(56 intermediate revisions by 3 users not shown)
Line 1: Line 1:
==Description==
+
{{OpenPagesTop}}
 
+
==Introduction==
 +
[[Image:Chronic Allergic Otitis.jpg|thumb|right|200px|Chronic allergic otitis in the dog. Source: Wikimedia Commons; Author: Caroldermoid (2006)]]
 
Atopic dermatitis is a heritable disorder in which animals are hypersenstive to common environmental allergens. It is one of the most common skin diseases of dogs worldwide.
 
Atopic dermatitis is a heritable disorder in which animals are hypersenstive to common environmental allergens. It is one of the most common skin diseases of dogs worldwide.
  
The most common allergens involved in atopic dermatitis are those of house dust mites (''Dermatophagoides farinae'') and grain mites. Human and animal danders, house dust, grass and tree pollen and moulds also frequently incite reactions. Susceptible animals produce allergen-specific IgE to these normally-innocuous allergens, which then binds to receptors on cutaneous mast cells. Atopic animals may have defects in the epidermis, leading to impaired barrier function, and it is thought that further allergen exposure occures via percutaneous absorption. This further exposure gives mast cell degranluation, releasing istamine, cytokines, chemokines, leukotrienes, prostaglandins and other chemical mediators. This is a type 1 (immediate) hypersensitivity reaction<sup>1</sup>, and leads to vasodilation, inflammatory cell infiltration and pruritus. It appears that the cytokines involved are abnormally biased towards a Th2 response. IL-4 in particular is produced; this cytokine is responsible for B-cell production of IgE. Bacterial superantigens and autoantigens released due to keratinocyte damage play a role in perpetuating inflammation.
+
The most common allergens involved in atopic dermatitis are those of house dust mites (''Dermatophagoides farinae'') and grain mites. Human and animal danders, house dust, grass and tree pollen and moulds also frequently incite reactions. Susceptible animals produce allergen-specific IgE to these normally-innocuous allergens, which then binds to receptors on cutaneous mast cells. Atopic animals may have defects in the epidermis, leading to impaired barrier function, and it is thought that further allergen exposure occurs via percutaneous absorption. This further exposure gives mast cell degranluation, releasing histamine, cytokines, chemokines, leukotrienes, prostaglandins and other chemical mediators. [[Type I Hypersensitivity|This is a type 1 (immediate) hypersensitivity]] reaction<sup>1</sup>, and leads to vasodilation, inflammatory cell infiltration and pruritus. It appears that the cytokines involved are abnormally biased towards a Th2 response. IL-4 in particular is produced; this cytokine is responsible for B-cell production of IgE. Bacterial superantigens and autoantigens released due to keratinocyte damage play a role in perpetuating inflammation.
  
 
==Signalment==
 
==Signalment==
 
+
Atopic dermatitis is a disease of dogs, although it can occur sporadically in the cat<sup>1</sup>. The typical age of onset of atopic dermatitis is between 6 months and 3 years of age and signs are hardly ever seen in animals under 6 months of age. Signs may be so mild at first that they are not noted, but usually progress to become clinically apparent<sup>1</sup>. Atopy is heritable and so breed predispositions occur. Susceptible breeds include the : Beauceron, Boston Terrier, Boxer, Cairn Terrier, Cocker Spaniel, Dalmation, English Bulldog, English Setter, Fox Terrier, Sealyham Terrier, Setters, Shar-Pei, West Highland White Terrier, Wire Haired Fox Terrier, and Yorkshire Terrier<sup>2</sup>. Certain breeds such as the Cocker Spaniel, Dachshund, Doberman Pinscher, German Shepherd, German Short-Haired Pointer and Poodle appear to have a decreased risk of atopy. There is no sex predilection.
Atopic dermatitis is a disease of dogs, although it can occur sporadically in the cat<sup>1</sup>. The typical age of onset of atopic dermatitis is between 6 months and 3 years of age and signs are hardly ever seen in animals under 6 months of age. Signs may be so mild at first thtat they are not noted, but usually progress to become clinically apparent<sup>1</sup>. Atopy is heritable and so breed predispoitions occur. Susceptible breeds include the : Beaceron, Boston Terrier, Boxer, Cairn Terrier, Cocker Spaniel, Dalmation, English Bulldog, English Setter, Fox Terrier, Sealyham Terrier, Setters, Shar-Pei, West Highland White Terrier, Wire Hiared fox Terrier, and Yorkshire Terrier<sup>2</sup>. Certain breeds such as the Cocker Spaniel, Dachshund, Doberman Pinscher, German Shepherd, German Short-haired Pointer and Poodle appear to have a decreased risk of atopy. There is no sex predilection.
 
  
 
==Diagnosis==
 
==Diagnosis==
 
+
The diagnosis of atopic dermatitis is based on the signalment, a thorough history and appropriate physical examination findings. Other causes of pruritus must also be ruled out. The differential diagnoses are<sup>1</sup>:
The diagnosis of atopic dermatitis is based on the signalment, athorough history and appropriate physical examination findings. Other causes of pruritus must also be ruled out. The differential diagnoses are<sup>1</sup>:
 
 
*Food allergy: ruled out by a dietary exclusion trial.
 
*Food allergy: ruled out by a dietary exclusion trial.
*Flea allergy dermatitis: ruled out observing response to ectoparasiticides.
+
*[[Flea Allergic Dermatitis|Flea allergy dermatitis]]: ruled out observing response to ectoparasiticides.
*Contact dermatitis: ruled out by confining animal to one area covered in e.g. newspaper.
+
*[[Contact Dermatitis|Contact dermatitis]]: ruled out by confining animal to one area covered in e.g. newspaper.
*Scabies:ruled out observing response to ectoparasiticides.
+
*[[Sarcoptic Mange|Scabies]]:ruled out observing response to ectoparasiticides.
  
Intradermal and serologic allergy testing are available but are not used to make a diagnosis of atopy. Their purpose is to identify the specific offending allergens in an animal in order than immunotherapy may be pursued. The results of allergy testing are only significant if the history and clinical signs are also suggestive of atopic dermatitis.  
+
Intradermal and serologic allergy testing are available but are not used to make a diagnosis of atopy. Their purpose is to identify the specific offending allergens in an animal in order that immunotherapy may be pursued. The results of allergy testing are only significant if the history and clinical signs are also suggestive of atopic dermatitis.  
  
 
===Clinical Signs===
 
===Clinical Signs===
 +
Signs are often, but not always, seasonal. Pruritus is the hallmark of atopic dermatitis and may be the only complaint. This gives rise to self-trauma, causing lesions. Lesions commonly include alopecia, erythema, scaling, crusting, excoriations and salivary staining. Macular-papular eruptions are occasionally seen<sup>2</sup>. With time, lichenification, and hyperpigmentation develops. Because the route of allergen contact is thought to be percutaneous absorption<sup>1, 2</sup>, it follows that hairless regions are most frequently affected: the face, ears, axillae, feet and inguinal regions are predilection sites. Secondary infections such as superficial staphylococcal pyoderma and [[Malassezia pachydermidis|''Malassezia'']] are common, and otitis externa often occurs concurrently<sup>2, 3, 4</sup>. A small number of cases exhibit only chronic or recurrent otitis externa. Another uncommon presentation is allergic rhinitis, manifesting as sneezing, nasal discharge or allergic conjunctivitis<sup>1, 2</sup>.
  
Signs are often, but not always, seasonal. Pruritus is the hallmark of atopic dermatitis and may be the only complaint. This gives rise to self-trauma, causing lesions. Lesions commonly include alopecia, erythema, scaling, crusting, excoriations and salivary staining. Macular-papular eruptions are occasionally seen<sup>2</sup>. With time, lichenification, and hyperpigmentation develops. Because the route of allergen contact is thought to be percutaneous absorption<sup>1, 2</sup>, it follows that hairless regions are most frequently affected: the face, ears, axillae, feet and inguinal regions are predilection sites. Secondary infections such as superficial staphylococcal pyoderma and ''Malassezia'' are common, and otitis externa often occurs concurrently<sup>2, 3, 4</sup>. A small number of cases exhibit only chronic or recurrent otitis externa. Another uncommon presentation is allergic rhinitis, manifesting as sneezing, nasal discharge or allergic conjunctivitis<sup>1, 2</sup>.
+
Signs commonly seen in different species are:
 +
:Dogs - face rubbing and foot licking; secondary [[Pyoderma|pyoderma]] or [[Seborrhea|seborrhea]]
 +
:Cats - facial, ear or generalised pruritus, [[Feline Miliary Dermatitis|miliary dermatitis]], [[Feline Eosinophilic Granuloma|eosinophilic granuloma complex]], symmetric alopecia
 +
:Horses - pruritic hea, pinnae, ventrum, legs, tailhead or recurrent [[Urticaria|urticaria]]
  
 
===Laboratory Tests===
 
===Laboratory Tests===
 +
Routine haematology and biochemistry rarely show any abnormalities in dogs, but eosinophilia is often seen in cats<sup>1</sup>. The measurement of total serum IgE levels is not useful in the diagnosis of atopic dermatitis as IgE levels do not significantly differ between atopic and normal animals<sup>2</sup>. IgE levels are also influenced by the presence of parasites, vaccinations and breed, and so this test is not reliable.
  
Routine haematology and biochemistry rarely show any abnormalities in dogs, but eosinophilia is often seen in cats<sup>1</sup>. The measurement of total serum IgE levels is not useful in the diagnosis of atopic dermatitis as IgE levels do not significantly differ betweem atopic and normal animals<sup>2</sup>. IgE levels are also influence by the presence of parasites, vaccinations and breed, and so this test is not reliable
+
Allergen-specific IgE tests are only useful when a diagnosis of atopic dermatitis has already been reached by consideration of history and clinical exam, and by ruling out other causes of pruritus. The test is used to identify allergens for immunotherapy by evaluating serum levels of IgE specific for a variety allergens. The exact technique varies between laboratories, but the principle is the same: serum is allowed to react with the allergen before excess serum and antibodies are rinsed away. An IgE-specific reagent linked to an indicator is added, and the amount that binds is proportional to the amount of allergen-specific IgE<sup>2</sup>. This can then be quantified. Several factors can adversely influence the test results. These include age, season, use of corticosteroids and laboratory inaccuracies.
 
 
Allergen-specific IgE tests are only useful when a diagnosis of atopic dermatitis has already been reached by consideration of histoty and clinical exam, and by ruling out other causes of pruritus. The test is used to identify allergens for immunotherapy by evaluating serum levels of IgE specific for a variety allergens. The exact technique varies between laboratories, but the principle is the same: serum is allowed to react with the allergen before excess serum and antibodies are rinsed away. An IgE-specific reagent linked to an indicator is added, and the amount that binds is proportional to the amount of allergen-sprecific IgE<sup>2</sup>. This can then be quantified. Several factors can adversely influence the test results. These include age, season, use of corticosteroids and laboratory inaccuracies.
 
  
 
===Other Tests===
 
===Other Tests===
 +
Intradermal skin tests determine the ability of allergens injected intradermally to cause mast cell degranulation leading to a subsequent wheal and flare reaction. It is therefore a close approximation of the pathogenesis of atopic dermatitis, and is a useful tests for revealing specific allergens for use in immunotherapy. Aqueous allergens are used for testing and include such things as house dust mites, pollens, moulds, insects and epidermal antigens. These should be stored in the fridge to maintain potency, and allowed to reach room temperature before testing<sup>2</sup>. Test results can be affected or inhibited by numerous factors such as medications, sedatives and stress. Drugs shown to affect intradermal skin testing include antihistamines, tricyclic antidepressants and glucocorticoids. Withdrawal times of 2, 4 and 6 weeks have been suggested for topical, oral and long-acting injectable steroids respectively<sup>3</sup>, although this may be difficult in a very pruritic animal. Some animals require sedation for intradermal skin testing and xylazine and medetomidine have been shown not to affect results. Diazepam and acepromzine should not be used<sup>2</sup>.
  
Intradermal skin tests determine the ability of allergens injected intradermally to cause mast cell degranulation leading to a subsequent wheal and flare reaction. It is therefore a close approximation of the pathogenesis of atopic dermatitis, and is a useful tests for revealing specific allergens for use in immunotherapy. Aqueous allergens are used for testing and include such things as house dust mites, pollens, moulds, insects and epidermal antigens. These should be stored in the fridge to maintain potency, and allowed to reach room temperature before testing<sup>2</sup>. Test results can be affected or inhibited by numerous factors such as medications, sedatives and stress. Drugs shown to affect intradermal skin testing include antihistamines, tricyclic antidepressants and glucocorticoids. Withdrawal times of 2, 4 and 8 weeks have been suggested for topical, oral and long-acting injectable steroids respectively, although this may be diffcult in a very pruritic animal. Some animals require sedation for intradermal skin testing and xylazine and medetomidine have been shown not to affect results. Diazepam and acepromzine should not be used<sup>2</sup>.
+
Fine needles are used to inject allergen intradermally. Histamine is used as a positive control, and isotonic saline as a negative. Approximately 0.05-1.0 ml solution is injected at each site, and after around 15 minues the test is read by scoring each allergen based on the size of the bleb.
 
 
26-27 gauge needles are used to inject allergen intradermally. Histamine is used as a positive control, and isotonic saline as a negative. Approximately 0.05-1.0 ml solution is injected at each site, and after around 15 minues the test is read by scoring each allergen based on the size of the bleb.
 
  
 
===Biopsy===
 
===Biopsy===
 
 
Biopsies may help rule out other differential diagnoses, but do not show any pathognomic changes for atopic dermatitis<sup>1</sup>.
 
Biopsies may help rule out other differential diagnoses, but do not show any pathognomic changes for atopic dermatitis<sup>1</sup>.
  
 
===Pathology===
 
===Pathology===
 +
Gross findings reflect the lesions seen in life and lesions are generally due to self-trauma.
  
Gross findings reflect the lesions seen in life.
+
Histological changes are non-specific but include acanthosis, a mixed mononuclear perivascular dermatitis, sebaceous gland metaplasia and secondary superficial pyoderma<sup>1</sup>.
  
Histologic changes are non-specific but include acanthosis, a mixed mononuclear perivascular dermatitis, sebaceous gland metaplasia and secondary superficial pyoderma<sup>1</sup>.
+
Other microscopical findings include: hyperplastic superficial perivascular dermatitis, mast cells, eosinophils and nonmetachromatic mononuclear cells. Perivascular inflammation may be involved especially in horses.
  
 
==Treatment==
 
==Treatment==
 
 
Several factors exist that in normal dogs may by insufficient to cause pruritus. However, when these occur at the same time as allergen exposure in atopic dogs, there can be an additive effect that breaks the threshold for pruritus. These "flare factors" include ectoparasites, microbial infections, stress and environmental effects. When treating for atopic dermatitis it is therefore critical to keep these factors to a minimum. Atopic dogs should be regularly treated with an ectoparasiticide against fleas and mites, and secondary bacterial or ''Malassezia'' infections should be identified and treated promptly. Stress should be avoided and products that may be irritant, such as cleaning materials, should not be used in the environment. This requires a certain amount of vigilance on the part of the owners.
 
Several factors exist that in normal dogs may by insufficient to cause pruritus. However, when these occur at the same time as allergen exposure in atopic dogs, there can be an additive effect that breaks the threshold for pruritus. These "flare factors" include ectoparasites, microbial infections, stress and environmental effects. When treating for atopic dermatitis it is therefore critical to keep these factors to a minimum. Atopic dogs should be regularly treated with an ectoparasiticide against fleas and mites, and secondary bacterial or ''Malassezia'' infections should be identified and treated promptly. Stress should be avoided and products that may be irritant, such as cleaning materials, should not be used in the environment. This requires a certain amount of vigilance on the part of the owners.
  
===Improving skin barrier function===
+
===Improving Cutaneous Barrier Function===
In normal animals, the skin has an important barrier function. The integrity of the epithelium may be impaired in atopic animals, facilitating further exposure to allergens. Finding ways to help improve the barrier function of the epidermis can contribute towards the effective management of atopy.
+
In normal animals, the skin has an important barrier function. The integrity of the epithelium may be impaired in atopic animals, facilitating further exposure to allergens. Finding ways to help improve the barrier function of the epidermis can contribute towards the effective management of atopy. Food trials are often used during the course of a work-up for atopic dermatitis to eliminate food allergy as a cause of pruritus. Many atopic animals non-specifically improve during food trials on prescription hypoallergenic diets, which may be attributable to several of their components. The inclusion of zinc and long-chain omega essential fatty acids is thought to reduce inflammation, and substances such as inositol, choline, histidine, pantothenate and nicotinamide may help improve epidermal lipid barrier<sup>3</sup>. The use of topical shampoos and emollients can also be beneficial. As well as physically removing allergens from the skin and coat, moisturising shampoos can hydrate the skin and improve the lipid barrier. Colloidal oatmeal may also have a direct antipruritic action<sup>3</sup>. Anti-microbial or anti-scaling shampoos, and ear cleaners can prove useful in certain cases depending on presentation. The effects of essential fatty acids in atopic dermatitis have been subjected to numerous clinical trials. EFA supplementation alters incorporation into cell membranes, which may reduce production of pro-inflammatory leukotrienes and prostaglandins<sup>3</sup>. The cutaneous lipid barrier may also be improved. However, there is some conflicting informtation, and high levels of supplementation may be neccessary to give beneficial effects.
  
Food trials are often used during the course of a work-up for atopic dermatitis to eliminate food allergy as a cause of pruritus. Many atopic animals non-specifically improve during food trials on prescription hypoallergenic diets, which may be attributable to several of their components. The inclusion of zinc and long-chain omega essential fatty acids is thought to reduce inflammation, and substances such as inositol, choline, histidine, pantothenate and nicotinamide may help improve epidermal lipid barrier<sup>4</sup>.
+
===Allergen Specific Therapy===
 +
In animals with demonstrated sensitivities to specific allergens, allergen-specific therapy can form part of the treatment regimen for atopic dermatitis. It may be possible to limit exposure to certain allergens. For example, exposure to house dust mites can be limited by keeping animals out of the bedroom and using hypoallergenic mattresses and pillow covers. Filtered vacuum cleaners can be used, and animals should be kept out of rooms for two to three hours after vacuuming. Soft toys harbour many dust mites and so should be avoided, or frozen for 24 hours once a month to keep the burden low. The animal's bedding should be washed at a temperature of greater than 70&deg;C and the bed wiped out regularly with a damp cloth. Environmental flea control products are effective at killing dust mites in the home. If the animal is allergic to pollens, walking routes can be altered to avoid contact with the specific source, be it grasses, trees or weeds. Dogs can be washed after walking through vegetation to remove allergens, and lawns can be mown short.
  
====Topical therapy====
+
Allergen specific immunotherapy (ASIT) can also be implemented. This involves the subcutaneous injection of gradually increasing quantities of allergen. The mechanism of action is not fully understood but it seems that administering large doses of allergen in an unusual route results in tolerance<sup>3</sup>. This may be because IgG level increase during the first few months of hyposensitization and binds circulating allergens, thereby blocking them from causing mast cell degranulation<sup>4</sup> The effects of ASIT are highly variable: around 25% of dogs can be controlled with immunotherapy alone, a further 50% show some improvement, and 25% are non-responsive. Effects can take some time to be appreciated, and so a 9 to 12 month trial of immunotherapy is recommended. Generally, injections are initially given 1-2 weeks apart, building up to the full dose. Animals are usually monitored for around 30mins after the first few treatments, because anaphylaxis is an uncommon side-effect. Once the full dose is reached, the interval between injections can be extended to roughly once monthly. Most animals require ongoing treatment at this interval to maintain the effects of ASIT, but a few animals can be gradually weaned off ASIT.
Topical therapy has a number of benefits although
 
it is time-consuming. Physical removal of allergens
 
is likely to be helpful. Hydration can be prolonged
 
by using moisturizing shampoos and conditioners.
 
These can also improve the skin lipid barrier.
 
Colloidal oatmeal may also have a direct antipruritic
 
action. Virbac’s Allermyl® range contains
 
linoleic acid (improves the skin lipid barrier),
 
vitamin E and mono-oligosaccharides (may reduce
 
TNF-α production and prevent microbial adherence)
 
and piroctone olamine (modulates the skin flora).
 
Chitosanides and microspherulites help prolong
 
retention and activity on the skin and coat. Other
 
topical products that may be helpful in individual
 
cases include ear cleaners and anti-microbial or
 
anti-scaling shampoos. The exact balance of
 
desired effects varies between individuals, so be
 
prepared to try different products and/or alternate
 
between antimicrobial and emollient shampoos.
 
  
====Essential fatty acids (EFA)====
+
===Anti-inflammatory therapy===
Numerous clinical trials and studies have evaluated
 
EFAs particularly the n-3 EFA eicosapentenoic acid
 
(EPA) and the n-6 EFA gamma-linolenic acid (GLA).
 
Supplementation can result in altered plasma levels
 
and incorporation into cell membranes, which may
 
lead to production of less inflammatory leucotrienes
 
and prostaglandins and improved cutaneous lipid
 
barrier. Recent studies, however, have not found
 
consistent changes in plasma, subcutaneous fat or
 
cutaneous EFAs following supplementation in atopic
 
and healthy dogs, and no correlation with the
 
clinical response (1-3).
 
Clinical results have been variable in controlled
 
trials, and no relationship between efficacy and
 
ratio of n-3/n-6 EFAs have been proven, although
 
high doses seem to be more effective. Recent
 
studies have shown that high quality, EFA enriched
 
diets are beneficial in canine AD although how
 
much of this is due to anti-inflammatory activity
 
or cutaneous barrier improvements is unclear (4).
 
  
===Allergen specific therapy===
+
In most cases, anti-inflammatory drugs are required in addition to topical treatments and allergen-specific therapy to control residual pruritus and inflammation. The dose and treatment regime should be adapted according to how successful other treatments are, the response to treatment and the presence of allergen in the environment (for example, pollen is present in the summer but not the winter). The aim should be to use the minimum dose that gives effective control of pruritus.
Allergen specific therapy will only be appropriate
 
in animals with identified sensitivities. The aim of
 
allergen testing is to identify allergens for avoidance
 
and immunotherapy, not to confirm the diagnosis.
 
  
====Allergen avoidance====
+
'''Glucocorticoids''' the most commonly used anti-inflammatory drugs in veterinary dermatology. Although they are cheap and efficacious, they are associated with many undesirable side effects. They should therefore be used with caution in atopic dermatitis. Drugs such as prednisolone or methyl-prednisolone can be used in the initial stages of treatment to break the itch-scratch cycle while animals begin to respond to other forms of control. They may also be used to manage seasonal atopy for a few months of the year. Short courses that gradually taper off can be implemented in flare-ups, or corticosteroids can be used as a very last resort in pets non-responsive to other forms of treatment. Topical steroids may be used where inflammation is localised to small areas of relatively hairless skin, or to control pyotraumatic dermatitis. In most cases, lesions are more widespread and so systemic administration is necessary. A dose should be established that induces remission, and this should be gradually tapered to the minimal effective dose, for example alternate day treatment. "Depot" injections of corticosteroids do not permit this flexibility in dosing, and should not be used. Glucocorticoids will suppress reactions to intradermal allergen tests and allergen-specific serology. However, the drugs are not thought to hamper the efficacy of vaccines.
Allergen avoidance measures can result in a significant
 
reduction in exposure to house dust mite (5).
 
Whether allergen avoidance results in clinically
 
significant improvement is controversial, although
 
one uncontrolled study demonstrated that allergen
 
avoidance was beneficial in canine AD (6).  
 
  
====Allergen specific immunotherapy (ASIT)====
+
'''Cyclosporine''' is an immunosuppressive drug that acts by suppressing T-cells, as well as mast cells and eosinophils. The doses used in atopy are immuno-modulating, and suppression of these cells impairs antigen presentation, IgE production and the development of inflammatory lesions<sup>3</sup>. Studies have suggested that cyclosporine is at least as effective as prednisolone for controlling atopic dermatitis<sup>3</sup>, but is better tolerated than the corticosteroid. The most likely side effects are transient anorexia and vomiting, but this can be avoided by administering cyclosporine with food. Uncommonly, hirsutism, alopecia, gingival hyperplasia, diarrhoea, tremors or erythema of the ears may be seen, but these effects are dose-dependent and reversible<sup>3</sup>. Immunosuppression is a potential concern, and so patients should be observed closely for opportunistic infections or infestations. Cyclosporine may also affect the efficacy of vaccination, and so some vets choose to treat with corticosteroids around this time instead. The drug minimally affects intradermal and serological allergy testing<sup>4</sup>.
ASIT involves the administration of gradually
 
increasing amounts of allergen by subcutaneous
 
injection. The mechanism of action is unknown
 
but it is thought that administering large doses
 
of allergen in an unusual route (i.e. subcutaneous
 
instead of epidermal) induces tolerance. Many
 
studies (albeit mostly open or retrospective)
 
have shown that 60-80% of dogs have a greater
 
than 50% improvement following ASIT. The
 
best results seem to occur with early treatment,
 
although a 9-12 month trial is necessary to assess
 
the response in each case. Animals on ASIT
 
require careful supervision to control microbial
 
infections and other flare factors, to administer
 
anti-inflammatory treatment as required and to
 
adjust the dose and/or frequency according
 
to the clinical response (Figure 1).
 
The exact protocol varies widely but usually
 
involves repeated injections a few days to 1-2
 
weeks apart. Once the full dose is reached, the
 
interval between injections can be extended.
 
A rush protocol, where the initial loading course
 
is given within a single day, was recently shown
 
to be as effective as conventional ASIT in a small
 
number of dogs (7). Recent reports also described
 
starting with a full dose (monodose therapy).
 
No adverse effects were seen in either case
 
although the dogs were pre-medicated with
 
an anti-histamine.
 
Alum precipitated vaccines have a depot effect
 
and require less frequent administration. Alum
 
adjuvants potentiate IgE responses in experimental
 
animals but no differences in efficacy between
 
alum-precipitated and aqueous vaccines have been
 
demonstrated in dogs. There are anecdotal reports
 
of improved efficacy with low dose ASIT, but a
 
controlled study, however, found no difference in
 
efficacy between low dose and conventional
 
alum-precipitated ASIT (8).
 
If ASIT proves successful, the interval between
 
injections can be extended. Increased pruritus
 
before the next injection is due indicates that the
 
interval is too long. The interval may also vary
 
through the year, especially in pollen sensitive
 
animals. Some dogs can be weaned off treatment,
 
but most require maintenance injections every
 
1-2 months.
 
Re-testing may reveal new sensitivities in dogs
 
with initially negative tests, dogs <12 months
 
old at the time of the original test, if there has
 
been a poor response to ASIT or where a good
 
response is not maintained. Re-formulating ASIT
 
can be beneficial in these dogs.
 
Adverse effects are uncommon. Injection site
 
reactions and anaphylactic shock are very rare,
 
although many dermatologists advise giving the
 
first 5-6 doses in a veterinary clinic. Increased
 
pruritus after an injection indicates that the dose is
 
too high although mild reactions can sometimes be
 
managed with antihistamines.
 
  
===Anti-inflammatory therapy===
+
Phytopica is a product containing a selection of Chinese herbs, which has been shown to be an efficacious, safe and palatable treatment for atopic dermatitis in dogs<sup>3</sup>. However, only a 20-50% improvement in signs is achieved, and so Phytopica is best used in combination with other control strategies and anti-inflammatory drugs.
Anti-inflammatory therapy is used as required
 
to control residual pruritus and inflammation.
 
Almost all atopics will require treatment in the
 
short to medium term, but the dose, frequency
 
and/or potency of drugs can be reduced if other
 
treatments are successful in the long term.
 
  
====Cyclosporine====
+
Hydrocortisone aceponate is a topical glucocorticoid that relieves pruritus. The topical administration and the fact that hydrocotisone aceponate is metabolised in the dermis means that many of the traditional side-effects of glucocorticoid therapy are avoided<sup>1, 3, 4</sup>. The product is potent, and rapidly exerts its effects following application. The formulation of the product makes it easy to apply, even to haired skin, and most animals only require every-other-day treatment. Adverse effects are rare, and only one dog has been reported to suffer a contact reaction.
Cyclosporine suppresses T-cells, which have been
 
implicated in the pathogenesis of canine AD.
 
I t also inhibits other key cells in allergic inflammatory reactions such as mast cells and
 
eosinophils. This has profound effects on antigen
 
presentation, IgE production, mononuclear cell
 
activity and the development of inflammatory
 
lesions, although at the doses used in canine AD,
 
cyclosporine is immuno-modulating rather than
 
immunosuppressive (Figure 2).
 
Cyclosporine is rapidly absorbed and distributed.
 
Bioavailability varies from 15-60% in individual
 
dogs and is not affected by food. There is little
 
correlation between trough levels and efficacy, and
 
dose adjustments are made according to the clinical
 
response rather than monitoring plasma levels.
 
Metabolism is via the cytochrome P450 system.
 
Numerous drugs can decrease metabolism, notably
 
itraconazole and ketoconazole, which increases
 
plasma concentrations, efficacy and the likelihood of
 
adverse effects (Figure 3). Phenobarbital increases
 
metabolism and decreases plasma levels.
 
Cyclosporine is administered for canine AD at a
 
dose of 5 mg/kg once daily. Controlled studies
 
have shown that it is at least as effective as
 
prednisolone and methyl-prednisolone (9,10),
 
although this may take 2-3 weeks to become
 
apparent. Glucocorticoids can be initially coadministered
 
to achieve more rapid remission.
 
Approximately one third of treated dogs require
 
daily dosing, one third every other day and one
 
third twice weekly to maintain remission.
 
Using cyclosporine as part of an integrated
 
management program can be more cost-effective
 
than relying on it alone.
 
The effect on intradermal testing and serology is
 
thought to be minimal, although the data is sparse.
 
Anecdotal data suggests that cyclosporine does
 
not affect the response to ASIT any more than
 
glucocorticoids although controlled studies have
 
not yet been performed.
 
Cyclosporine is well tolerated by the majority of dogs.
 
Transient anorexia and vomiting are the most likely
 
problems. Persistent vomiting is uncommon but
 
may be eased by administering with food, and/or by
 
using the gastrointestinal protectant sucralfate
 
or H-2 blocking agents such as ranitidine. Other
 
uncommon adverse effects include hirsuitism,
 
increased shedding of hair and transient alopecia,
 
gingival hyperplasia, papillomatosis, diarrhea,
 
lameness and muscle tremors, and erythema
 
and edema of the ears. These are largely dosedependent
 
and reversible. The nephropathy,
 
hepatopathy and hypertension seen in humans
 
have not been recognized in dogs except at doses
 
>20 mg/kg. Immunosuppression is a potential concern.
 
Inhibition of cell-mediated immunity in particular
 
could result in bacterial and protozoal infections,
 
dermatophytosis and demodicosis. In practice,
 
however, the risk appears to be very small and most
 
atopic dogs experience fewer secondary infections
 
following treatment. Feline and human patients on
 
long term treatment have a small risk of developing
 
lymphoma and cutaneous neoplasms. Lymphoplasmatoid
 
dermatitis has been seen following
 
doses >20 mg/kg and there is a single case report
 
of lymphoma in an older dog following treatment
 
for anal furunculosis. These have, however, not
 
been reported in atopic dogs (11). Inhibition of
 
T-helper cell function and β-cell activation could
 
affect the response to vaccination. Some authors
 
advocate withdrawing treatment for up to two
 
weeks either side of vaccination, although this
 
will lead to worsening of the skin condition. The
 
pros and cons for each individual case should
 
be discussed with the owner.
 
  
====Phytopica™====
+
Antihistamines have some efficacy in the face of atopic dermatitis, and may have synergistic activity with essential fatty acids and glucocorticoids<sup>3, 4</sup>.
Phytopica™, a compound derived from Rehmannia
 
glutinosa, Paeonia lactiflora and Glycyrrhiza
 
uralensis improved canine AD in a preliminary
 
study (14). In a recent randomized, double-blind
 
and placebo-controlled trial of 120 dogs Phytopica™
 
(200 mg/kg/day) appeared to be an efficacious,
 
safe and palatable non-steroidal treatment for
 
canine AD, although the effect was modest with
 
most dogs achieving a 20-50% improvement in
 
clinical signs (15). Responses are typically evident
 
within four weeks (Figure 4). Adverse effects are
 
self-limiting gastro-intestinal disturbances such as
 
diarrhea and vomiting. This is generally a better
 
safety profile than has been reported for other
 
anti-inflammatory therapies (16).
 
  
====Glucocorticoids====
+
==Prognosis==
Corticosteroids, synthesized in the adrenal cortex,
+
If left untreated, the degree of pruritus worsens, but atopic dermatitis is not life threatening unless intractable pruritus warrants euthanasia<sup>1</sup>. Some cases may spontaneously resolve.
have glucocorticoid (anti-inflammatory and
 
gluconeogenic) and mineralocorticoid (salt
 
and water balance) activity. Glucocorticoids are
 
simultaneously the most used and abused drugs in veterinary dermatology. They are cheap, easy
 
to administer and highly efficacious but are
 
associated with a plethora of side-effects (17,18).
 
At pharmacological doses they inhibit the expression
 
of genes encoding a variety of molecules
 
involved in immunity and inflammation, resulting
 
in rapid and profound immunosuppression and
 
decreased inflammation.
 
Most quoted doses are for prednisolone (Table 1);
 
the dose for other steroids is calculated according
 
to the relative potency. Steroids also vary in
 
their mineralocorticoid activity and duration of
 
activity, but that suppression of the hypothalamicpituitary-
 
adrenal (HPA) axis may last longer
 
than the therapeutic effect. Only prednisolone
 
and methyl-prednisolone are suitable for long term
 
alternate day dosing as their duration of activity
 
should leave at least 12 hours for the HPA axis
 
to recover. The formulation also has an impact:
 
soluble esters (such as succinates and phosphates)
 
have a rapid onset and shorter duration of
 
action; acetates have a moderate onset and
 
duration; and acetonides and dipropionates are
 
long-acting depot preparations.
 
Glucocorticoids are highly effective in canine
 
AD, but must be used with care and, ideally,
 
as a last resort. Exploring alternative approaches
 
will help minimize the dose and frequency
 
required. Genuine seasonal AD that requires
 
3-4 months treatment each year, however, can
 
usually be managed successfully with minimal
 
problems. Short courses (0.5-1.0 mg/kg once
 
daily for 3-5 days) can also be administered to
 
treat flares of inflammation in dogs otherwise
 
well controlled on other medication.
 
Topical treatment directs the steroid to affected skin
 
and avoids the need for systemic therapy. Topical
 
glucocorticoids can be used where inflammation is
 
localized to relatively hairless skin, pyotraumatic
 
dermatitis (‘hot-spots’) or in the ears and eyes.
 
More potent products containing betamethasone
 
etc. can be used once or twice daily initially, but
 
hydrocortisone is better for long term, alternate day
 
treatment. Fuciderm® (contains betamethasone) is
 
a good choice as the gel formulation allows rapid
 
penetration and drying.
 
Systemic therapy is necessary with more severe
 
or widespread lesions. 0.5-1.0 mg/kg prednisolone
 
is given once daily until remission. You can then
 
administer the same dose every other day and then
 
reduce the dose by 50% every 7-14 days until the
 
lowest maintenance dose is established; or,
 
gradually wean the alternate day dose off, and
 
then establish the lowest every other day
 
maintenance dose. The only suitable systemic
 
drugs for alternate day dosing are prednisolone
 
or methyl-prednisolone, but triamcinolone,
 
betamethasone or dexamethasone can be used
 
to achieve remission in severe cases. Injectable
 
preparations should not be used unless absolutely
 
necessary, as it cannot be withdrawn, the dose
 
cannot be altered, nor the hypothalamic-pituitaryadrenal
 
(HPA) axis allowed to recover.
 
Glucocorticoids will suppress reactions to intradermal
 
allergen tests, although the effect on serology is believed to be less marked. It is currently
 
recommended that you withdraw topical glucocorticoids
 
for at least two weeks, short acting oral
 
glucocorticoids for at least three weeks and longer
 
acting injectable glucocorticoids for at least six
 
weeks before allergy testing. Dogs on long term
 
treatment or with iatrogenic hyperadrenocorticism
 
may need considerably longer withdrawal
 
times (Figure 5). Glucocorticoids are frequently
 
administered to control inflammation during the
 
induction phase of immunotherapy. This does not
 
appear to affect the response rate although there
 
are no controlled studies.
 
Adverse effects arise from the glucocorticoid
 
and mineralocorticoid activity as well as
 
suppression of the HPA axis and endogenous
 
steroid production. Common acute side-effects
 
include polyuria and polydipsia. The risk of
 
these problems developing can be reduced by
 
using methyl-prednisolone, which has much less
 
mineralocorticoid activity. Other acute sideeffects
 
include polyphagia and weight gain
 
(which can be managed using a low calorie diet),
 
panting and behavioral changes (including
 
dullness and, rarely, aggression). The onset of
 
iatrogenic hyperadrenocorticism is dose and
 
duration dependent, but there is a wide
 
variation in tolerance between individuals.
 
Immunosuppression and secondary infections
 
are quite common with long term treatment.
 
Inhibition of cell-mediated immunity can result
 
in demodicosis, dermatophytosis and infections
 
with intracellular organisms. Immunosuppression
 
and alterations in cutaneous barrier function
 
commonly result in superficial pyoderma.
 
Production of dilute urine is a factor that
 
contributes to cystitis.
 
Some of these infections may be clinically
 
inapparent, as steroid therapy may mask some of
 
the associated inflammation and characteristic
 
clinical signs such as pruritus or dysuria.
 
Because humoral immunity is less affected,
 
animals can develop adequate antibody titers
 
following vaccination. For this reason, short
 
term treatment may be used to control the
 
clinical signs if cyclosporine has to be withdrawn
 
because of routine vaccination.
 
 
 
====Hydrocortisone aceponate====
 
Hydrocortisone aceponate is a novel topical
 
diester glucocorticoid for the treatment of pruritus
 
in dogs. Topical diester glucocorticoids overcome
 
many of the adverse effects traditionally
 
associated with systemic or topical glucocorticoid
 
therapy. They are rapidly absorbed and exert
 
potent anti-inflammatory effects within the
 
epidermis and superficial dermis. Metabolism
 
within the dermis, however, ensures that very
 
little active compound reaches deeper tissues
 
and the circulation, minimizing skin thinning
 
and systemic effects. The topical formulation,
 
furthermore, eases topical administration. The
 
small dose volume, very small droplet size and
 
volatile carrier help to ensure quick and easy
 
application, penetration of even haired skin and
 
rapid drying with minimal cutaneous after
 
effects. The spray is formulated such that two
 
sprays from 10 cm away will penetrate the coat
 
and treat a 10 x 10 cm (i.e. palm sized area of
 
skin). Early studies (unpublished) demonstrated good
 
efficacy and safety in short term treatment of
 
various pruritic disorders in dogs including
 
pyotraumatic dermatitis and f lea allergic
 
dermatitis. An open-label pilot study and
 
preliminary findings from a randomized, doubleblind,
 
placebo controlled study found that
 
Cortavance® was effective and well-tolerated in
 
managing canine AD. One dog has suffered a
 
contact reaction, but adverse effects have not
 
otherwise been noted. Once daily administration
 
was sufficient to induce remission, after which a
 
proportion of dogs can be maintained on every
 
other day therapy. Twice weekly administration,
 
however, resulted in a relapse in most dogs.
 
  
====Antihistamines====
+
{{Learning
A large review of clinical trials (16) concluded
+
|Vetstream = [https://www.vetstream.com/canis/Content/Disease/dis00214.asp Atopy]<br>[https://www.vetstream.com/canis/Content/Illustration/ill02158.asp Atopy: acute on chronic]<br>[https://www.vetstream.com/canis/Content/Illustration/ill02166.asp ears]<br>[https://www.vetstream.com/canis/Content/Illustration/ill02164.asp Atopy: extremities]<br>[https://www.vetstream.com/canis/Content/Illustration/ill02165.asp Atopy: peri-orbital]
that there is no more than fair evidence of
+
|literature search = [http://www.cabdirect.org/search.html?q=title:(%22Atopic+Dermatitis%22) Atopic Dermatitis publications]
medium efficacy for the first generation antihistamines
 
clemastine and a combination
 
of chlorpheniramine and hydroxyzine, and
 
the second generation (non-sedating) drug
 
oxatomide. There may however be some synergistic
 
activity with EFAs and glucocorticoids.
 
Adverse effects of first generation drugs are
 
uncommon and are usually linked to drowsiness.
 
Adverse effects to second generation drugs
 
are more common and include gastrointestinal
 
tract upsets and cardiac arrhythmias.
 
  
==Prognosis==
+
[http://www.cabdirect.org/search.html?q=title:(%22Atopic+Dermatitis%22)+AND+od:(dogs) Atopic Dermatitis in dogs publications]
  
If left untreated, the degree of pruritus worsens, but atopic dermatitis is not life threatening unless intractable pruritus warrants euthanasia<sup>1</sup>. Some cases may spontaneously resolve.
+
[http://www.cabdirect.org/search.html?q=title:(%22Atopic+Dermatitis%22)+AND+od:(cats) Atopic Dermatitis in cats publications]
 +
}}
  
 
==Links==
 
==Links==
Line 459: Line 94:
 
#Merck & Co (2008) '''The Merck Veterianry Manual (Eight Edition)''', ''Merial''.
 
#Merck & Co (2008) '''The Merck Veterianry Manual (Eight Edition)''', ''Merial''.
  
 +
 +
{{review}}
 +
 +
{{OpenPages}}
 
[[Category:Allergic Skin Diseases]]
 
[[Category:Allergic Skin Diseases]]
 
+
[[Category:Dermatological Diseases - Dog]][[Category:Immunological Diseases - Dog]] [[Category:Dermatological Diseases - Cat]][[Category:Immunological Diseases - Cat]]
[[Category:To Do - Blood]][[Category:To Do - Lizzie]]
+
[[Category:Expert Review]]
 +
[[Category:Type I Hypersensitivity Diseases]]
 +
[[Category:Integumentary System - Hypersensitivity Reactions]]

Latest revision as of 17:26, 8 September 2015


Introduction

Chronic allergic otitis in the dog. Source: Wikimedia Commons; Author: Caroldermoid (2006)

Atopic dermatitis is a heritable disorder in which animals are hypersenstive to common environmental allergens. It is one of the most common skin diseases of dogs worldwide.

The most common allergens involved in atopic dermatitis are those of house dust mites (Dermatophagoides farinae) and grain mites. Human and animal danders, house dust, grass and tree pollen and moulds also frequently incite reactions. Susceptible animals produce allergen-specific IgE to these normally-innocuous allergens, which then binds to receptors on cutaneous mast cells. Atopic animals may have defects in the epidermis, leading to impaired barrier function, and it is thought that further allergen exposure occurs via percutaneous absorption. This further exposure gives mast cell degranluation, releasing histamine, cytokines, chemokines, leukotrienes, prostaglandins and other chemical mediators. This is a type 1 (immediate) hypersensitivity reaction1, and leads to vasodilation, inflammatory cell infiltration and pruritus. It appears that the cytokines involved are abnormally biased towards a Th2 response. IL-4 in particular is produced; this cytokine is responsible for B-cell production of IgE. Bacterial superantigens and autoantigens released due to keratinocyte damage play a role in perpetuating inflammation.

Signalment

Atopic dermatitis is a disease of dogs, although it can occur sporadically in the cat1. The typical age of onset of atopic dermatitis is between 6 months and 3 years of age and signs are hardly ever seen in animals under 6 months of age. Signs may be so mild at first that they are not noted, but usually progress to become clinically apparent1. Atopy is heritable and so breed predispositions occur. Susceptible breeds include the : Beauceron, Boston Terrier, Boxer, Cairn Terrier, Cocker Spaniel, Dalmation, English Bulldog, English Setter, Fox Terrier, Sealyham Terrier, Setters, Shar-Pei, West Highland White Terrier, Wire Haired Fox Terrier, and Yorkshire Terrier2. Certain breeds such as the Cocker Spaniel, Dachshund, Doberman Pinscher, German Shepherd, German Short-Haired Pointer and Poodle appear to have a decreased risk of atopy. There is no sex predilection.

Diagnosis

The diagnosis of atopic dermatitis is based on the signalment, a thorough history and appropriate physical examination findings. Other causes of pruritus must also be ruled out. The differential diagnoses are1:

  • Food allergy: ruled out by a dietary exclusion trial.
  • Flea allergy dermatitis: ruled out observing response to ectoparasiticides.
  • Contact dermatitis: ruled out by confining animal to one area covered in e.g. newspaper.
  • Scabies:ruled out observing response to ectoparasiticides.

Intradermal and serologic allergy testing are available but are not used to make a diagnosis of atopy. Their purpose is to identify the specific offending allergens in an animal in order that immunotherapy may be pursued. The results of allergy testing are only significant if the history and clinical signs are also suggestive of atopic dermatitis.

Clinical Signs

Signs are often, but not always, seasonal. Pruritus is the hallmark of atopic dermatitis and may be the only complaint. This gives rise to self-trauma, causing lesions. Lesions commonly include alopecia, erythema, scaling, crusting, excoriations and salivary staining. Macular-papular eruptions are occasionally seen2. With time, lichenification, and hyperpigmentation develops. Because the route of allergen contact is thought to be percutaneous absorption1, 2, it follows that hairless regions are most frequently affected: the face, ears, axillae, feet and inguinal regions are predilection sites. Secondary infections such as superficial staphylococcal pyoderma and Malassezia are common, and otitis externa often occurs concurrently2, 3, 4. A small number of cases exhibit only chronic or recurrent otitis externa. Another uncommon presentation is allergic rhinitis, manifesting as sneezing, nasal discharge or allergic conjunctivitis1, 2.

Signs commonly seen in different species are:

Dogs - face rubbing and foot licking; secondary pyoderma or seborrhea
Cats - facial, ear or generalised pruritus, miliary dermatitis, eosinophilic granuloma complex, symmetric alopecia
Horses - pruritic hea, pinnae, ventrum, legs, tailhead or recurrent urticaria

Laboratory Tests

Routine haematology and biochemistry rarely show any abnormalities in dogs, but eosinophilia is often seen in cats1. The measurement of total serum IgE levels is not useful in the diagnosis of atopic dermatitis as IgE levels do not significantly differ between atopic and normal animals2. IgE levels are also influenced by the presence of parasites, vaccinations and breed, and so this test is not reliable.

Allergen-specific IgE tests are only useful when a diagnosis of atopic dermatitis has already been reached by consideration of history and clinical exam, and by ruling out other causes of pruritus. The test is used to identify allergens for immunotherapy by evaluating serum levels of IgE specific for a variety allergens. The exact technique varies between laboratories, but the principle is the same: serum is allowed to react with the allergen before excess serum and antibodies are rinsed away. An IgE-specific reagent linked to an indicator is added, and the amount that binds is proportional to the amount of allergen-specific IgE2. This can then be quantified. Several factors can adversely influence the test results. These include age, season, use of corticosteroids and laboratory inaccuracies.

Other Tests

Intradermal skin tests determine the ability of allergens injected intradermally to cause mast cell degranulation leading to a subsequent wheal and flare reaction. It is therefore a close approximation of the pathogenesis of atopic dermatitis, and is a useful tests for revealing specific allergens for use in immunotherapy. Aqueous allergens are used for testing and include such things as house dust mites, pollens, moulds, insects and epidermal antigens. These should be stored in the fridge to maintain potency, and allowed to reach room temperature before testing2. Test results can be affected or inhibited by numerous factors such as medications, sedatives and stress. Drugs shown to affect intradermal skin testing include antihistamines, tricyclic antidepressants and glucocorticoids. Withdrawal times of 2, 4 and 6 weeks have been suggested for topical, oral and long-acting injectable steroids respectively3, although this may be difficult in a very pruritic animal. Some animals require sedation for intradermal skin testing and xylazine and medetomidine have been shown not to affect results. Diazepam and acepromzine should not be used2.

Fine needles are used to inject allergen intradermally. Histamine is used as a positive control, and isotonic saline as a negative. Approximately 0.05-1.0 ml solution is injected at each site, and after around 15 minues the test is read by scoring each allergen based on the size of the bleb.

Biopsy

Biopsies may help rule out other differential diagnoses, but do not show any pathognomic changes for atopic dermatitis1.

Pathology

Gross findings reflect the lesions seen in life and lesions are generally due to self-trauma.

Histological changes are non-specific but include acanthosis, a mixed mononuclear perivascular dermatitis, sebaceous gland metaplasia and secondary superficial pyoderma1.

Other microscopical findings include: hyperplastic superficial perivascular dermatitis, mast cells, eosinophils and nonmetachromatic mononuclear cells. Perivascular inflammation may be involved especially in horses.

Treatment

Several factors exist that in normal dogs may by insufficient to cause pruritus. However, when these occur at the same time as allergen exposure in atopic dogs, there can be an additive effect that breaks the threshold for pruritus. These "flare factors" include ectoparasites, microbial infections, stress and environmental effects. When treating for atopic dermatitis it is therefore critical to keep these factors to a minimum. Atopic dogs should be regularly treated with an ectoparasiticide against fleas and mites, and secondary bacterial or Malassezia infections should be identified and treated promptly. Stress should be avoided and products that may be irritant, such as cleaning materials, should not be used in the environment. This requires a certain amount of vigilance on the part of the owners.

Improving Cutaneous Barrier Function

In normal animals, the skin has an important barrier function. The integrity of the epithelium may be impaired in atopic animals, facilitating further exposure to allergens. Finding ways to help improve the barrier function of the epidermis can contribute towards the effective management of atopy. Food trials are often used during the course of a work-up for atopic dermatitis to eliminate food allergy as a cause of pruritus. Many atopic animals non-specifically improve during food trials on prescription hypoallergenic diets, which may be attributable to several of their components. The inclusion of zinc and long-chain omega essential fatty acids is thought to reduce inflammation, and substances such as inositol, choline, histidine, pantothenate and nicotinamide may help improve epidermal lipid barrier3. The use of topical shampoos and emollients can also be beneficial. As well as physically removing allergens from the skin and coat, moisturising shampoos can hydrate the skin and improve the lipid barrier. Colloidal oatmeal may also have a direct antipruritic action3. Anti-microbial or anti-scaling shampoos, and ear cleaners can prove useful in certain cases depending on presentation. The effects of essential fatty acids in atopic dermatitis have been subjected to numerous clinical trials. EFA supplementation alters incorporation into cell membranes, which may reduce production of pro-inflammatory leukotrienes and prostaglandins3. The cutaneous lipid barrier may also be improved. However, there is some conflicting informtation, and high levels of supplementation may be neccessary to give beneficial effects.

Allergen Specific Therapy

In animals with demonstrated sensitivities to specific allergens, allergen-specific therapy can form part of the treatment regimen for atopic dermatitis. It may be possible to limit exposure to certain allergens. For example, exposure to house dust mites can be limited by keeping animals out of the bedroom and using hypoallergenic mattresses and pillow covers. Filtered vacuum cleaners can be used, and animals should be kept out of rooms for two to three hours after vacuuming. Soft toys harbour many dust mites and so should be avoided, or frozen for 24 hours once a month to keep the burden low. The animal's bedding should be washed at a temperature of greater than 70°C and the bed wiped out regularly with a damp cloth. Environmental flea control products are effective at killing dust mites in the home. If the animal is allergic to pollens, walking routes can be altered to avoid contact with the specific source, be it grasses, trees or weeds. Dogs can be washed after walking through vegetation to remove allergens, and lawns can be mown short.

Allergen specific immunotherapy (ASIT) can also be implemented. This involves the subcutaneous injection of gradually increasing quantities of allergen. The mechanism of action is not fully understood but it seems that administering large doses of allergen in an unusual route results in tolerance3. This may be because IgG level increase during the first few months of hyposensitization and binds circulating allergens, thereby blocking them from causing mast cell degranulation4 The effects of ASIT are highly variable: around 25% of dogs can be controlled with immunotherapy alone, a further 50% show some improvement, and 25% are non-responsive. Effects can take some time to be appreciated, and so a 9 to 12 month trial of immunotherapy is recommended. Generally, injections are initially given 1-2 weeks apart, building up to the full dose. Animals are usually monitored for around 30mins after the first few treatments, because anaphylaxis is an uncommon side-effect. Once the full dose is reached, the interval between injections can be extended to roughly once monthly. Most animals require ongoing treatment at this interval to maintain the effects of ASIT, but a few animals can be gradually weaned off ASIT.

Anti-inflammatory therapy

In most cases, anti-inflammatory drugs are required in addition to topical treatments and allergen-specific therapy to control residual pruritus and inflammation. The dose and treatment regime should be adapted according to how successful other treatments are, the response to treatment and the presence of allergen in the environment (for example, pollen is present in the summer but not the winter). The aim should be to use the minimum dose that gives effective control of pruritus.

Glucocorticoids the most commonly used anti-inflammatory drugs in veterinary dermatology. Although they are cheap and efficacious, they are associated with many undesirable side effects. They should therefore be used with caution in atopic dermatitis. Drugs such as prednisolone or methyl-prednisolone can be used in the initial stages of treatment to break the itch-scratch cycle while animals begin to respond to other forms of control. They may also be used to manage seasonal atopy for a few months of the year. Short courses that gradually taper off can be implemented in flare-ups, or corticosteroids can be used as a very last resort in pets non-responsive to other forms of treatment. Topical steroids may be used where inflammation is localised to small areas of relatively hairless skin, or to control pyotraumatic dermatitis. In most cases, lesions are more widespread and so systemic administration is necessary. A dose should be established that induces remission, and this should be gradually tapered to the minimal effective dose, for example alternate day treatment. "Depot" injections of corticosteroids do not permit this flexibility in dosing, and should not be used. Glucocorticoids will suppress reactions to intradermal allergen tests and allergen-specific serology. However, the drugs are not thought to hamper the efficacy of vaccines.

Cyclosporine is an immunosuppressive drug that acts by suppressing T-cells, as well as mast cells and eosinophils. The doses used in atopy are immuno-modulating, and suppression of these cells impairs antigen presentation, IgE production and the development of inflammatory lesions3. Studies have suggested that cyclosporine is at least as effective as prednisolone for controlling atopic dermatitis3, but is better tolerated than the corticosteroid. The most likely side effects are transient anorexia and vomiting, but this can be avoided by administering cyclosporine with food. Uncommonly, hirsutism, alopecia, gingival hyperplasia, diarrhoea, tremors or erythema of the ears may be seen, but these effects are dose-dependent and reversible3. Immunosuppression is a potential concern, and so patients should be observed closely for opportunistic infections or infestations. Cyclosporine may also affect the efficacy of vaccination, and so some vets choose to treat with corticosteroids around this time instead. The drug minimally affects intradermal and serological allergy testing4.

Phytopica is a product containing a selection of Chinese herbs, which has been shown to be an efficacious, safe and palatable treatment for atopic dermatitis in dogs3. However, only a 20-50% improvement in signs is achieved, and so Phytopica is best used in combination with other control strategies and anti-inflammatory drugs.

Hydrocortisone aceponate is a topical glucocorticoid that relieves pruritus. The topical administration and the fact that hydrocotisone aceponate is metabolised in the dermis means that many of the traditional side-effects of glucocorticoid therapy are avoided1, 3, 4. The product is potent, and rapidly exerts its effects following application. The formulation of the product makes it easy to apply, even to haired skin, and most animals only require every-other-day treatment. Adverse effects are rare, and only one dog has been reported to suffer a contact reaction.

Antihistamines have some efficacy in the face of atopic dermatitis, and may have synergistic activity with essential fatty acids and glucocorticoids3, 4.

Prognosis

If left untreated, the degree of pruritus worsens, but atopic dermatitis is not life threatening unless intractable pruritus warrants euthanasia1. Some cases may spontaneously resolve.


Atopic Dermatitis Learning Resources
VetstreamVetlexicon advert button.png
Vetstream
To reach the Vetstream content, please select
Canis, Felis, Lapis or Equis
CABICABI logo.jpg
Literature Search
Search for recent publications via CAB Abstract
(CABI log in required)
Atopic Dermatitis publications

Atopic Dermatitis in dogs publications

Atopic Dermatitis in cats publications


Links

References

  1. Tilley, L P and Smith, F W K (2004) The 5-minute Veterinary Consult (Fourth Edition),Blackwell.
  2. Beale, K M (2006) Atopic Dermatitis: Clinical Signs and Diagnosis. Proceedings of the North American Veterinary Conference 2006.
  3. Willemse, T (2007) The Newest on Canine Atopic Dermatitis. Proceedings of the Southern European Veterinary Conference & Congreso Nacional AVEPA.
  4. Merck & Co (2008) The Merck Veterianry Manual (Eight Edition), Merial.




Error in widget FBRecommend: unable to write file /var/www/wikivet.net/extensions/Widgets/compiled_templates/wrt66478a0caa75c2_21858686
Error in widget google+: unable to write file /var/www/wikivet.net/extensions/Widgets/compiled_templates/wrt66478a0cae1d82_88884611
Error in widget TwitterTweet: unable to write file /var/www/wikivet.net/extensions/Widgets/compiled_templates/wrt66478a0cb1b569_55823057
WikiVet® Introduction - Help WikiVet - Report a Problem